Carlsmed (CARL), a commercial-stage medical technology company that says it is “pioneering AI-enabled personalized spine surgery solutions” and is “focused on becoming the standard of care for spine fusion surgery,” priced 6.7M shares at $15.00. The deal priced within the $14.00-$16.00 range. BofA, Goldman Sachs and Piper Sandler acted as joint book running managers for the offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks